Rheonix

The CDC says that the number of people in the US who have been infected with diseases carried by mosquitoes, ticks, and flea bites have more than tripled in recent years.

The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.

Rheonix has won an administrative supplement to an existing SBIR grant to develop the Zika test using its CARD cartridge and Encompass Optimum platform.

The firm's dual assay for host antigen to HIV as well as viral RNA was described in a proof-of-principle study earlier this year. 

Rheonix Raises $28.6M

The Ithaca, New York-based firm will use the financing to ramp up commercialization of its molecular diagnostic testing platforms.

The firm is aiming at in vitro diagnostics, applied markets, and next-generation sequencing sample preparation.

The Phase II grant will provide the company with funding to develop a commercial-ready version of the test.

The fully automated self-confirming assay will simultaneously detect HIV/AIDS antibodies and viral RNA in a single specimen.

HandyLab has been awarded

NEW YORK (GenomeWeb) – Rheonix will soon begin a clinical trial for a microarray-based test for sexually transmitted infections with the aim of submitting the assay to the US Food and Drug Administration for clearance next year.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.